Drug
Cort125281
Cort125281: highest development phase Phase 1, developed by Corcept Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| CORT125281, 40mg, fasted NCT03335956 | Phase 1 | Healthy |
Latest
No recent events.
Follow Cort125281 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.